Earnings Beat at Alexion, View Upped - Analyst Blog

By
A A A

Alexion Pharmaceuticals, Inc. 's ( ALXN ) second-quarter 2013 earnings (excluding special items but including stock-based compensation expense) of 64 cents per share beat the Zacks Consensus Estimate by 4 cents and the year-ago adjusted earnings by 23 cents per share.

Higher product sales boosted second quarter earnings. Including one-time items, second-quarter 2013 earnings came in at 48 cents per share, up 167%.

Alexion's revenues jumped 35% to approximately $370.1 million in the second quarter of 2013 driven by strong Soliris sales. Revenues surpassed the Zacks Consensus Estimate of $365 million.

Adjusted operating expenses climbed 22.7% to $174.5 million in the second quarter of 2013. The increase was attributable to a rise in both research and development (R&D) expenses (up 12.8%) and selling, general and administrative (SG&A) expenses (up 29.2%). The increase in R&D expenses was attributable to the company's efforts to develop its pipeline.

Pipeline Update

Alexion currently has several candidates in clinical development focusing on different areas. The company is also working on expanding Soliris' label into additional indications like Shiga-toxin producing e. coli hemolytic uremic syndrome, neuromyelitis optica and myasthenia gravis.

Alexion's pipeline also includes asfotase alfa (hypophosphatasia), ALXN1102/ALXN1103 (hematology) and ALXN1007 (inflammatory disorders). We are impressed by Alexion's efforts to develop its pipeline.

Guidance Raised

Apart from announcing financial results for the second quarter, Alexion raised its outlook for 2013. The company raised its revenue guidance to $1.520-$1.530 billion from the previous forecast of $1.505-$1.520 billion.

The company also raised its adjusted earnings guidance for 2013 from $2.87-$2.97 per share to $2.97 to $3.02 per share. Soliris should continue performing well, driving growth at Alexion.

Alexion currently carries a Zacks Rank #3 (Hold). Companies like Jazz Pharmaceuticals ( JAZZ ), Actelion Ltd . ( ALIOF ) and WuXi PharmaTech ( Cayman ) Inc . ( WX ) appear to be more attractive with a Zacks Rank #1 (Strong Buy).



ACTELION LTD (ALIOF): Get Free Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

WUXI PHARMATECH (WX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Earnings , Stocks

Referenced Stocks: ALIOF , ALXN , JAZZ , WX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Can You Trust CarFax?
Can You Trust CarFax?               

Stocks

Referenced

Most Active by Volume

54,628,795
  • $15.825 ▲ 1.97%
34,389,460
  • $55.93 ▲ 4.74%
23,082,870
  • $36.94 ▲ 5.18%
18,793,101
  • $30.16 ▼ 0.56%
16,543,440
  • $8.26 ▲ 1.60%
16,528,437
  • $100.44 ▼ 0.13%
13,961,227
  • $34.83 ▲ 0.96%
13,785,273
  • $10.59 ▲ 15.49%
As of 8/21/2014, 12:24 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com